Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | TP53 | P04637 | 1/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | CTSB | P07858 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 4/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.45 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.45 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.45 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.45 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.45 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.45 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2911184 | 0.83 | TSHR (0.63) | ALDH1A1TP53TDP1POLBKDM4E | |
| SCHEMBL1805996 | 0.81 | ALDH1A1 (0.50) | ALDH1A1TP53TDP1POLBKDM4E | |
| SCHEMBL1806915 | 0.79 | ALDH1A1 (0.48) | ALDH1A1TDP1POLBKDM4EMAPT | |
| SCHEMBL10507474 | 0.78 | ALDH1A1 (0.63) | ALDH1A1TP53TDP1POLBKDM4E | |
| SCHEMBL2771204 | 0.77 | ALDH1A1 (0.68) | ALDH1A1TP53TDP1POLBKDM4E | |
| SCHEMBL224469 | 0.77 | ALDH1A1 (1.00) | ALDH1A1TP53TDP1POLBKDM4E | |
| Hydrochloric Acid SCHEMBL699002 | 0.76 | ALDH1A1 (0.95) | ALDH1A1TP53TDP1POLBKDM4E | |
| SCHEMBL6584266 | 0.76 | ALDH1A1 (0.95) | ALDH1A1TP53TDP1POLBKDM4E | |
| SCHEMBL201278 | 0.76 | ALDH1A1 (0.65) | ALDH1A1TP53TDP1POLBKDM4E | |
| SCHEMBL343127 | 0.76 | CA1 (0.61) | ALDH1A1TDP1KDM4ECTSBCASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4790179-B2 | — | — | 2011-10-12 | — | — | JP | claimed |
| EP-2305246-A1 | Tumor necrosis factor inhibitors | Ception Therapeutics, Inc. (US) | 2011-04-06 | — | — | EP | claimed |
| EP-2298295-A1 | Tumor necrosis factor inhibitors | Ception Therapeutics, Inc. (US) | 2011-03-23 | — | — | EP | claimed |
| US-20090221527-A1 | TUMOR NECROSIS FACTOR INHIBITORS | CEPTION THERAPEUTICS, INC. (US) | 2009-09-03 | — | — | US | claimed |
| US-7566741-B2 | Methods of inhibiting osteoclast activity | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2009-07-28 | — | — | US | claimed |
| EP-1845970-A4 | TUMOR NECROSIS FACTOR INHIBITORS | CEPTION THERAPEUTICS INC (US) | 2009-02-18 | — | — | EP | claimed |
| EP-1845970-A2 | TUMOR NECROSIS FACTOR INHIBITORS | Ception Therapeutics, Inc. (US) | 2007-10-24 | — | — | EP | claimed |
| WO-2006083970-A2 | TUMOR NECROSIS FACTOR INHIBITORS | CEPTION THERAPEUTICS, INC. (US) | 2006-08-10 | — | — | WO | claimed |
| WO-2006083869-A2 | TUMOR NECROSIS FACTOR INHIBITORS | CEPTION THERAPEUTICS, INC. (US) | 2006-08-10 | — | — | WO | claimed |
| EP-1207873-A4 | METHODS OF INHIBITING OSTEOCLAST ACTIVITY | UNIV PENNSYLVANIA (US) | 2006-04-12 | — | — | EP | claimed |
| US-20050080133-A1 | Methods of inhibiting osteoclast activity | GREENE MARK I (US) | 2005-04-14 | — | — | US | claimed |
| JP-2003505503-A | — | — | 2003-02-12 | — | — | JP | claimed |
| EP-1207873-A1 | METHODS OF INHIBITING OSTEOCLAST ACTIVITY | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2002-05-29 | — | — | EP | claimed |
| WO-2001008677-A1 | METHODS OF INHIBITING OSTEOCLAST ACTIVITY | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2001-02-08 | — | — | WO | claimed |
| EP-2305246-B1 | Tumor necrosis factor inhibitors | UNIV PENNSYLVANIA (US) | 2015-08-26 | — | — | EP | disclosed |
| US-9096607-B2 | Tumor necrosis factor inhibitors | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140256803-A1 | TUMOR NECROSIS FACTOR INHIBITORS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2014-09-11 | — | — | US | disclosed |
| EP-1091974-A2 | CAVITY INDUCED ALLOSTERIC MODIFICATION OF INTERMOLECULAR INTERACTIONS AND METHODS OF IDENTIFYING COMPOUNDS THAT EFFECT THE SAME | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2001-04-18 | — | — | EP | disclosed |
| WO-2001008677-A1 | METHODS OF INHIBITING OSTEOCLAST ACTIVITY | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2001-02-08 | — | — | WO | disclosed |
| WO-2000001349-A2 | CAVITY INDUCED ALLOSTERIC MODIFICATION OF INTERMOLECULAR INTERACTIONS AND METHODS OF IDENTIFYING COMPOUNDS THAT EFFECT THE SAME | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221527-A1 | TUMOR NECROSIS FACTOR INHIBITORS | TNFRSF1A, TNF, TNFRSF9 | ALDH1A1 3912/4885TP53 52/4885TDP1 3407/4885 |
| US-20140256803-A1 | TUMOR NECROSIS FACTOR INHIBITORS | TNFRSF1A, TNF, TNFRSF9 | ALDH1A1 3912/4885TP53 52/4885TDP1 3407/4885 |
| US-20050080133-A1 | Methods of inhibiting osteoclast activity | NFATC1, CD40LG, CD14 | ALDH1A1 4486/4885TP53 3613/4885TDP1 3064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.